TN2012000057A1 - Antibodies against the ectodomain of erbb3 and uses thereof - Google Patents

Antibodies against the ectodomain of erbb3 and uses thereof

Info

Publication number: TN2012000057A1
Authority: TN; Tunisia
Prior art keywords: erbb3; antibodies; receptor; antigen binding; binding fragments
Prior art date: 2009-08-21

Application number

TNP2012000057A

Other languages

English (en)

Inventor

Birgit Schoeberl

Ulrik Nielsen

Michael Feldhaus

Original Assignee

Merrimack Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-21

Filing date

2012-02-09

Publication date

2013-09-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-02-09 Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc

2013-09-19 Publication of TN2012000057A1 publication Critical patent/TN2012000057A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2012000057A 2009-08-21 2012-02-09 Antibodies against the ectodomain of erbb3 and uses thereof TN2012000057A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23579909P	2009-08-21	2009-08-21
PCT/US2010/046364 WO2011022727A2 (fr)	2009-08-21	2010-08-23	Anticorps contre lectodomaine de erbb3 et leurs utilisations

Publications (1)

Publication Number	Publication Date
TN2012000057A1 true TN2012000057A1 (en)	2013-09-19

Family

ID=43607614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2012000057A TN2012000057A1 (en)	2009-08-21	2012-02-09	Antibodies against the ectodomain of erbb3 and uses thereof

Country Status (21)

Country	Link
EP (1)	EP2467164A2 (fr)
JP (1)	JP5752687B2 (fr)
KR (1)	KR20120059568A (fr)
CN (1)	CN103002912A (fr)
AU (1)	AU2010284018C1 (fr)
BR (1)	BR112012003809A2 (fr)
CA (1)	CA2771744A1 (fr)
CR (1)	CR20120108A (fr)
DO (1)	DOP2012000044A (fr)
EA (1)	EA201200195A1 (fr)
EC (1)	ECSP12011740A (fr)
IL (1)	IL218097A0 (fr)
IN (1)	IN2012DN01518A (fr)
MA (1)	MA33582B1 (fr)
MX (1)	MX336091B (fr)
NI (1)	NI201200027A (fr)
PE (1)	PE20121585A1 (fr)
SG (1)	SG178509A1 (fr)
TN (1)	TN2012000057A1 (fr)
WO (1)	WO2011022727A2 (fr)
ZA (1)	ZA201201195B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20131113T1 (hr)	2007-02-16	2014-01-17	Merrimack Pharmaceuticals, Inc.	Protutijela protiv erbb3 i njihova uporaba
NO2719708T3 (fr) *	2009-11-13	2018-03-24
HRP20160737T1 (hr)	2009-12-22	2016-07-15	Roche Glycart Ag	Anti-her3-protutijela i njihove uporabe
NZ602084A (en)	2010-03-11	2014-07-25	Merrimack Pharmaceuticals Inc	Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (es)	2010-04-09	2016-04-14	Aveo Pharmaceuticals, Inc.	Anticuerpos anti-ErbB3
PH12013500333A1 (en)	2010-08-20	2013-04-22	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
IT1402149B1 (it) *	2010-10-04	2013-08-28	Ist Fisioterap Ospitalroma	Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
EP2635605B1 (fr) *	2010-11-01	2018-07-25	Symphogen A/S	Anticorps anti-her3 et compositions
DK2699602T3 (en)	2011-04-19	2017-06-06	Merrimack Pharmaceuticals Inc	BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES
JPWO2012176779A1 (ja) *	2011-06-20	2015-02-23	協和発酵キリン株式会社	抗ｅｒｂＢ３抗体
MX357391B (es)	2011-09-30	2018-07-06	Regeneron Pharma	Anticuerpos anti-erbb3 y usos de los mismos.
US9273143B2 (en)	2011-09-30	2016-03-01	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
JP6169085B2 (ja)	2011-10-06	2017-07-26	アベオファーマシューティカルズ，インコーポレイテッド	抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
AU2012335543C1 (en) *	2011-11-09	2017-12-14	Beijing Cotimes Biotech Co., Ltd.,	HER3 antibodies and uses thereof
TW201328706A (zh)	2011-12-05	2013-07-16	Novartis Ag	表皮生長因子受體３（ｈｅｒ３）之抗體
US20150037336A1 (en) *	2012-02-22	2015-02-05	U3 Pharma Gmbh	Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es)	2013-01-11	2015-07-29	Hoffmann La Roche	Terapia de combinación de anticuerpos anti-her3
WO2015058108A1 (fr) *	2013-10-17	2015-04-23	Sanford-Burnham Medical Research Institute	Biomarqueurs de la sensibilité à des médicaments et procédé d'identification et d'utilisation desdits biomarqueurs de la sensibilité à des médicaments
WO2015100459A2 (fr)	2013-12-27	2015-07-02	Merrimack Pharmaceuticals, Inc.	Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
EP3110846B1 (fr)	2014-02-28	2020-08-19	Merus N.V.	Anticorps qui se lient aux egfr et erbb3
CN105367657B (zh) *	2014-08-14	2019-09-13	上海生物制品研究所有限责任公司	抗her3抗体、其制法及其应用
CA2959716A1 (fr)	2014-09-08	2016-03-17	Yeda Research And Development Co. Ltd.	Anticorps anti-her3 et leurs utilisations
EP3191523B1 (fr)	2014-09-08	2019-08-07	Yeda Research and Development Co., Ltd.	Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki)
US10184006B2 (en)	2015-06-04	2019-01-22	Merrimack Pharmaceuticals, Inc.	Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
HUE055222T2 (hu)	2015-10-23	2021-11-29	Merus Nv	Megkötõ molekulák, amelyek gátolják a rák növekedését
CN110650752A (zh)	2017-03-31	2020-01-03	美勒斯公司	用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
EA201992522A1 (ru)	2017-05-17	2020-04-22	Мерус Н.В.	КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EP3665198B9 (fr)	2017-08-09	2025-05-21	Merus N.V.	Anticorps liant egfr et cmet
CA3072267A1 (fr)	2017-08-09	2019-02-14	University Of Saskatchewan	Agents de liaison a her3 et utilisations associees
GB201804094D0 (en) *	2018-03-14	2018-04-25	Ultrahuman Thirteen Ltd	ERBB3 Binding agents
WO2019241893A2 (fr) *	2018-06-22	2019-12-26	Crd Pharmaceuticals Inc	Anticorps anti-her3 et ses utilisations
AU2021360625A1 (en) *	2020-10-14	2023-06-01	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
MX2023005940A (es) *	2020-11-20	2023-07-27	Actinium Pharmaceuticals Inc	Radioinmunoterapia con her3 para el tratamiento de canceres solidos.
US20240293565A1 (en) *	2021-06-15	2024-09-05	Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd.	Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
CN119013307A (zh) *	2022-04-13	2024-11-22	上海翰森生物医药科技有限公司	抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20131113T1 (hr) *	2007-02-16	2014-01-17	Merrimack Pharmaceuticals, Inc.	Protutijela protiv erbb3 i njihova uporaba

2010
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/fr not_active Ceased
- 2010-08-23 CA CA2771744A patent/CA2771744A1/fr not_active Abandoned
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 EP EP10810721A patent/EP2467164A2/fr not_active Withdrawn
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown

Also Published As

Publication number	Publication date
IN2012DN01518A (fr)	2015-06-05
CN103002912A (zh)	2013-03-27
DOP2012000044A (es)	2012-06-30
JP5752687B2 (ja)	2015-07-22
MA33582B1 (fr)	2012-09-01
PE20121585A1 (es)	2012-11-29
AU2010284018C1 (en)	2015-10-15
SG178509A1 (en)	2012-04-27
MX336091B (es)	2016-01-08
AU2010284018A1 (en)	2012-03-22
IL218097A0 (en)	2012-04-30
WO2011022727A2 (fr)	2011-02-24
JP2013506622A (ja)	2013-02-28
EP2467164A2 (fr)	2012-06-27
KR20120059568A (ko)	2012-06-08
CA2771744A1 (fr)	2011-02-24
BR112012003809A2 (pt)	2019-09-24
ZA201201195B (en)	2015-07-29
WO2011022727A3 (fr)	2013-06-27
CR20120108A (es)	2012-06-05
MX2012002172A (es)	2012-05-29
NI201200027A (es)	2013-01-29
ECSP12011740A (es)	2013-02-28
EA201200195A1 (ru)	2012-12-28
AU2010284018B2 (en)	2014-06-05

Publication	Publication Date	Title
TN2012000057A1 (en)	2013-09-19	Antibodies against the ectodomain of erbb3 and uses thereof
MX2009008656A (es)	2009-11-10	Anticuerpos contra erbb3 y usos de los mismos.
PH12019501115A1 (en)	2020-07-13	Anti-cd134 (ox40) antibodies and uses thereof
AU2018253639A1 (en)	2018-11-22	Compositions and methods for antibodies targeting EPO
MX350957B (es)	2017-09-27	Moleculas de union especificas para her3 y usos de las mismas.
PH12015500390A1 (en)	2015-04-27	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX2015006548A (es)	2015-10-15	Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
EP2560684A4 (fr)	2013-11-20	Échafaudages multimériques à base de domaine de fibronectine de type iii
MX2012007340A (es)	2012-08-01	Anticuerpos anti/her3 y usos de los mismos.
MX2013004897A (es)	2013-07-15	Anticuerpos y composiciones anti-her3.
MX347515B (es)	2017-04-28	Agentes que se unen al receptor encrespado y usos de los mismos.
WO2012058592A3 (fr)	2012-08-16	Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci
MX375439B (es)	2025-03-04	Moleculas de union cd37 y sus inmunoconjugados.
AU2011338480A8 (en)	2017-03-23	Humanized antibodies to LIV-1 and use of same to treat cancer
MD20150102A2 (ro)	2016-02-29	Anticorpi umanizaţi anti-CD134 (OX40) şi utilizarea acestora
MX2014015830A (es)	2015-03-05	Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
IN2014CN04373A (fr)	2015-09-04
CY1119154T1 (el)	2018-02-14	Anti-vla-4 αντισωματα
PH12015500752A1 (en)	2015-05-25	Her3 antigen binding proteins binding to the beta-hairpin of her3
IN2014DN09717A (fr)	2015-07-31
MX2015005756A (es)	2015-09-16	Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4.
IN2014CN04374A (fr)	2015-09-04
WO2015048008A3 (fr)	2015-07-16	Molécules de liaison spécifiques de her3 et utilisation desdites molécules
ZA201900838B (en)	2025-10-29	Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
HK1166273A (en)	2012-10-26	Antibodies against the ectodomain of erbb3 and uses thereof